Bristol Myers Squibb Stock Remains Undervalued After Positive Data From Clinical Trials

The stock price of Bristol Myers Squibb (NYSE: BMY) has seen a 3% rise in yesterday's trading session (Jun 10), after the company announced positive data from phase three clinical trials of Breyanzi as a second line treatment in adults with relapsed or refractory large B-cell lymphoma...